
MLYS Stock Forecast & Price Target
MLYS Analyst Ratings
Bulls say
Mineralys Therapeutics is positioned favorably due to the promising results of lorundrostat, which has demonstrated a significant placebo-adjusted blood pressure benefit exceeding 10mmHg in patients with uncontrolled and resistant hypertension. The drug's differentiated profile has garnered attention from key opinion leaders (KOLs) and stands in contrast to Phase 3 competitor data, suggesting a competitive advantage in the market. Furthermore, near-term FDA feedback and an anticipated New Drug Application (NDA) submission add to the positive outlook for the company's future financial performance and market potential.
Bears say
Mineralys Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, primarily stemming from the potential failure of its product candidate, lorundrostat, to achieve anticipated commercial revenue. Concerns include the difficulty of accessing adequate capital resources necessary for operational funding, which is critical for ongoing program development and commercialization efforts. Additionally, there are uncertainties related to market size and pricing strategies, which could adversely affect the overall market penetration of their treatment for uncontrolled hypertension.
This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MLYS Analyst Forecast & Price Prediction
Start investing in MLYS
Order type
Buy in
Order amount
Est. shares
0 shares